Agilent Purchases Diagnostics Company Multiplicom
Agilent Technologies Inc. (Santa Clara, California, USA) and Multiplicom N.V. (Niel, Belgium) have announced that they have signed a definitive agreement for Agilent to acquire Multiplicom, a European diagnostics company involved in genetic testing. Agilent is acquiring Multiplicom for approximately €68 million in cash.
Agilent Technologies Inc. (Santa Clara, California, USA) and Multiplicom N.V. (Niel, Belgium) have announced that they have signed a definitive agreement for Agilent to acquire Multiplicom, a European diagnostics company involved in genetic testing. Agilent is acquiring Multiplicom for approximately €68 million in cash.
Multiplicom develops, manufactures, and commercializes molecular-diagnostic solutions, provided as kits, which enable personalized medicine. Specifically, these solutions enable clinical labs to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or identify congenital defects early in pregnancy.
Herman Verrelst, vice president and general manager of Agilent’s Genomics Division, said, “The acquisition of Multiplicom significantly strengthens our presence in the genomics market. Multiplicom’s products and technology help expand our target-enrichment portfolio and enhance our next-generation sequencing workflow capabilities - providing immediate scale in adjacent markets.”
“Multiplicom is excited to be a part of Agilent and for the opportunity to offer our products and technology to a global customer base,” said Dirk Pollet, Multiplicom’s CEO. “We are also immensely grateful to our investors Gimv, PMV, Qbic, RMM, University of Antwerpen and VIB for their unwavering support from Day One.”
For more information, please visit: www.agilent.com
GC–TOF-MS Finds 250 Volatile Compounds in E-Cigarette Liquids
November 1st 2024A study has used gas chromatography coupled to a time-of-flight mass spectrometer to build an electron ionization mass spectra database of more than 250 chemicals classified as either volatile or semi-volatile compounds. An additional, confirmatory layer of liquid chromatography–mass spectrometry analysis was subsequently performed.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Multivariate Design of Experiments for Gas Chromatographic Analysis
November 1st 2024Recent advances in green chemistry have made multivariate experimental design popular in sample preparation development. This approach helps reduce the number of measurements and data for evaluation and can be useful for method development in gas chromatography.
